Deulorlatinib vs Iruplinalkib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK;ROS1 · full Non-Small Cell Lung Cancer pipeline
Deulorlatinib
Developed by Shenzhen TargetRx and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Iruplinalkib
Marketed by Qilu Pharmaceutical
NCT04632758 · Phase 3 · status unknown
This open-label, randomized phase 3 trial assigned 292 patients with ALK-positive advanced non-small cell lung cancer who had not had an ALK inhibitor to iruplinalkib (WX-0593) or crizotinib. Patients and doctors knew which drug was given, but progression was assessed by an independent review committee. At the planned interim analysis, progression-free survival, the primary measure, was significantly longer with iruplinalkib (median 27.7 vs 14.6 months; hazard ratio 0.34; p<0.0001), so the result is met. The figures come from the peer-reviewed report of the trial in the Journal of Thoracic Oncology.
Next expected readout: March 2027 · NCT05765877 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) (from randomization until firstly recorded disease progression or death (whichever occurs earlier), or to the date that the last patients observed for 12 months): INSPIRE interim analysis, primary, IRC-assessed progression-free survival: median 27.7 months with iruplinalkib (WX-0593) vs 14.6 months with crizotinib; hazard ratio 0.34 (98.02% CI 0.23 to 0.52; p<0.0001), met. (met)
Result source: NCT04632758
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Deulorlatinib | Iruplinalkib |
|---|---|---|
| PFS, median | —Trial running · NCT06082635 | —Not reported |
| OS, median | —Trial running · NCT06082635 | —Not reported |
| ORR | —Trial running · NCT06082635 | —Not reported |
| Duration of response, median | —Trial running · NCT06082635 | —Not reported |
PFS, median
- Deulorlatinib
- —Trial running · NCT06082635
- Iruplinalkib
- —Not reported
OS, median
- Deulorlatinib
- —Trial running · NCT06082635
- Iruplinalkib
- —Not reported
ORR
- Deulorlatinib
- —Trial running · NCT06082635
- Iruplinalkib
- —Not reported
Duration of response, median
- Deulorlatinib
- —Trial running · NCT06082635
- Iruplinalkib
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Deulorlatinib: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Deulorlatinib's landscape · Iruplinalkib's landscape